Jetrea (ocriplasmin intravitreal) Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) March 2016 ADVERSE REACTIONS Postmarketing Experience Night blindness has been identified during post-approval use of Jetrea....
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts